GRAY - Graybug vision posts mid-stage wet AMD study preliminary topline results

Graybug Vision (GRAY) posts preliminary topline data from the 12-month treatment phase of its Phase 2b ALTISSIMO trial of GB-102 for the treatment of wet age-related macular degeneration (wet AMD), the company's proprietary microparticle depot formulation of sunitinib malate injected intravitreally.The ALTISSIMO trial is a masked and controlled Phase 2b dose-ranging study of two doses of GB-102 with a single control arm of patients on aflibercept, conducted across 33 study sites in the United States.Analysis of the ALTISSIMO 1mg arm showed that the primary endpoint of median time to first supportive therapy was 5 months.48% of patients did not require supportive therapy for at least 6 months, and 62% of patients for at least 4 months or more, at least once during the trial. The company also added that the 1mg dose performed better than the 2mg dose.The trial will continue through a six-month extension in which 28 of the 50 patients

For further details see:

Graybug vision posts mid-stage wet AMD study preliminary topline results